Search

Displaying results 3701 - 3710 of 10000 in total
  1. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    Fluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes. … [L12849] Fluorodopa F 18 PET is used adjunctly with other diagnostic investigations and serves primarily to visualize dopaminergic nerve terminals in the striatum.[L12849]

    Synonyms: L-6-(18F)Fluoro-DOPA, 6-Fluoro-(18F)-L-3,4-Dihydroxyphenylalanine
  2. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    Adrafinil is a mild central nervous system stimulating drug typically employed to relieve excessive sleepiness and inattention in geriatric patients. … It was marketed in France and elsewhere in Europe under the trade name Olmifon until September 2011 when France's FDA equivalent reassessed the drug and withdrew marketing permission.

  3. Drug

    Tenofovir

    go.drugbank.com/drugs/DB14126
    Investigational

    [A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. … [A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order

  4. Drug

    Votucalis

    go.drugbank.com/drugs/DB05032
    Investigational

    rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.

  5. Drug

    Amrubicin

    go.drugbank.com/drugs/DB06263
    Investigational

    Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. … In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC.

  6. Drug

    ATG002

    go.drugbank.com/drugs/DB05068
    Investigational

    ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. … Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.

  7. Drug

    Thioproperazine

    go.drugbank.com/drugs/DB01622
    Approved

    Thioproperazine is a potent neuroleptic with antipsychotic properties. … It is virtually without antiserotonin and hypotensive action and has no antihistaminic property.

    Synonyms: N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide, N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamide
  8. Drug

    Penicillium glaucum

    go.drugbank.com/drugs/DB14171
    Approved

    Penicillium glaucum allergenic extract is used in allergenic testing.

  9. Drug

    LC16M8

    go.drugbank.com/drugs/DB05019
    Investigational

    It is the only attenuated vaccine to be licensed for use in humans to prevent smallpox infection. … LC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines.

  10. Drug

    Potassium bitartrate

    go.drugbank.com/drugs/DB11107
    ApprovedInvestigational

    Potassium bitartrate has a long history of medical use as a laxative administered as a rectal suppository and is an approved third-class OTC drug in Japan. … Potassium bitartrate was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120]